Additionally, WEE1i combination with sorafenib restored the sensitivity of KRAS-mutant cells to this multi-target tyrosine kinase inhibitor, suggesting a potential strategy for treating KRAS-mutant NSCLC [29]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.